David Pernock
Chairman and Chief Executive Officer
Chairman of the Board and Chief Executive Officer David Pernock is the driving force behind Fibrocell Science’s vision to advance the science of fibroblasts for regenerative medicine and cell-based therapies for aesthetic, medical and scientific needs. In 2011, Fibrocell Science received FDA approval for LAVIV® (azficel-T), the first and only cell-based product in aesthetics and one of only eight cell therapy products approved by the FDA.
Under Pernock’s leadership, the company is focused on growing the value of its proprietary fibroblast platform by expanding from its strengths in aesthetics to new indications for high value medical conditions with unmet needs. Its robust pipeline includes potential treatments for acne scarring, restrictive burn scars, vocal fold scarring and rare genetic collagen deficiencies, such as Recessive Dystrophic Epidermolysis Bullosa (RDEB). Future growth is also expected from the company’s partnership with the Clinical Investigations for Dermal Mesenchymally-Obtained Derivatives (CIDMOD) Initiative (www.CIDMOD.org). At his initiative, CIDMOD was formed in collaboration with researchers from a number of different universities across the U.S. to advance the development of new personalized cell therapies and diagnostic tools. In conjunction with its recent $45 million capital raise, Fibrocell Science has also formed a promising strategic partnership with Intrexon Corporation to further the development of high value fibroblast-based products.
Pernock is a respected international business executive with extensive experience in pharmaceuticals and healthcare. Prior to being appointed CEO and chairman of Fibrocell Science, Pernock was senior vice president, GlaxoSmithKline Pharmaceuticals responsible for its vaccines (biologics), oncology, acute care and HIV businesses. Previously, he held a number of senior executive positions at GlaxoSmithKline including vice president of marketing, pharmaceuticals; vice president of sales and marketing, oncology; vice president of managed care; and vice president of sales. Pernock has been the recipient of numerous awards and is active in many philanthropic organizations. He earned a Bachelor of Science in Business Administration from Arizona State University.
Declan Daly
Chief Operating Officer and Chief Financial Officer
Chief Operating Officer and Chief Financial Officer Declan Daly has extensive global business experience and has worked in the dermatology industry for nearly 15 years. Previously, he served as CEO of Isolagen, the predecessor to Fibrocell Science. Daly also served as Isolagen’s CFO; executive vice president – Europe; and COO and CFO. Prior to joining Isolagen, Daly held numerous executive positions with Inamed Corporation. This included serving as CFO, senior vice president, corporate controller and principal accounting officer, and vice president of finance and administration of Inamed International Corporation based in Europe. Daly holds a Bachelor of Arts in Management Science and Industrial Systems Studies from Trinity College in Dublin and is a fellow of the Institute of Chartered Accountants in Ireland.
John Maslowski
Vice President, Scientific Affairs
John Maslowski, vice president of scientific affairs, plays a pivotal role in leading the research and development of future indications based on the company’s proprietary fibroblast platform. In this position, he collaborates with scientific advisors, designs protocols, negotiates study design with the FDA and oversees the conduct of clinical studies. In addition, Maslowski oversees process development initiatives aimed at reducing manufacturing costs and cycle time while increasing yields. Previously, Mr. Maslowski was vice president of operations with oversight of manufacturing and quality. Maslowski was employed at Wyeth Pharmaceuticals from 2001 to 2005, serving most recently as quality assurance investigations manager in support of manufacturing. Previously, Maslowski held positions with Merck Research Laboratories and Teva Pharmaceuticals. Maslowski holds a Bachelor of Science in Biology from Ursinus College and Master of Science in Biology from Villanova University.
Laura Campbell
Vice President, Planning
Laura Campbell, vice president of planning, works closely with Fibrocell Science’s CEO on internal coordination and oversight of execution for strategic initiatives. Her leadership is instrumental in assuring that cross-functional teams are resourced and working together to deliver against corporate objectives. This includes planning internal processes for clinical studies, new product development, information technology and operations. Campbell also leads the company’s organizational effectiveness and design. Campbell brings nearly 20 years of experience in human resources operations in the pharmaceutical industry. Prior to joining Fibrocell Science, she held various leadership positions at GlaxoSmithKline. Campbell holds a Bachelor of Science in Human Resources from LaSalle University and Master of Science in Human Organizational Science from Villanova University.
Karen Donhauser
Vice President, Quality
Karen Donhauser, vice president of quality, is responsible for overseeing all aspects of quality control and quality assurance for Fibrocell Science. She leads a team involved in ensuring compliance with Good Manufacturing Practices and stringent adherence to FDA requirements, as well as execution of product release testing. Donhauser joined Fibrocell Science in 2005 as the manager of quality control prior to the initiation of the clinical studies for FDA approval of LAVIV®; thus, she has nearly eight years of company experience from pre- to post-product launch. In addition to cell culture, her expertise includes aseptic processing and practices, pharmaceutical microbiology and creating and implementing Quality Systems. Prior to joining Fibrocell Science, Donhauser was employed by Wyeth Pharmaceuticals for eight years and held positions in both quality control and manufacturing. She served most recently as manager of the microbiology laboratory in the sterile injectable penicillin facility where she was responsible for all microbiological release testing on finished product, with emphasis on sterility assurance. Donhauser holds a Bachelor of Science degree in Biology from Juniata College.
Michele McHugh-Mazzatta
Vice President, Sales
Michele McHugh-Mazzatta, vice president of sales, leads the sales organization in providing highly personalized service to the company’s customer base of dermatologists and plastic surgeons. In this role, she is responsible for planning sales strategy and achieving the sales forecast; building the customer base; and pricing and leading the sales force. She also leads special projects relating to capacity planning. McHugh-Mazzatta has more than 25 years of sales and marketing experience in the pharmaceutical and biotechnology industries. Prior to joining Fibrocell Science, McHugh-Mazzatta served as CEO of Four M Group LLC, a business consulting firm that she founded. Previously, she held numerous sales leadership positions at GlaxoSmithKline including, regional vice president, sales, general pharmaceutical products; managing director, vaccine direct sales; and various other positions involving cross-functional leadership. McHugh-Mazzatta earned a Bachelor of Science in Nutrition and a certification in business management both from Rutgers University.